Pharmaceuticals Licensing Terms And Agreements Trends Report 2026 With Directory Of 2,700 Deals Signed Since 2020 - Track Deal Structures, Payment Benchmarks And Active Industry Dealmakers

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 12, 2026 (GLOBE NEWSWIRE) -- The "Licensing Deals in Pharmaceuticals 2020-2026" report has been added to ResearchAndMarkets's offering.
The report provides a comprehensive analysis of licensing agreements across the global pharmaceutical industry. Designed for business development, licensing, legal, and strategy professionals, the report delivers detailed insight into how companies structure licensing partnerships, negotiate financial terms, and allocate development and commercialization rights.
The report includes details of more than 2,700 licensing deals announced between 2020 and 2026, providing an extensive view of licensing activity across the pharmaceutical sector. Each deal record includes financial terms where available and links to online deal records and contract documents filed with regulators when publicly disclosed.
By combining detailed deal data, financial benchmarking, and access to real contract documents, the report provides valuable intelligence for evaluating potential partners, structuring licensing agreements, and negotiating stronger deal terms.

Why This Report Matters
Licensing agreements are a cornerstone of pharmaceutical innovation, enabling companies to access new technologies, share development risk, and accelerate product commercialization.
By providing comprehensive deal data, financial benchmarking, and access to real contract documents, this report delivers the intelligence needed to structure stronger licensing partnerships and negotiate more effectively.
Key Benefits

• Save Significant Research Time: Access over 2,700 licensing deals in a single resource, eliminating the need to search multiple databases, press releases, and regulatory filings.
• Benchmark Licensing Deal Structures: Understand how pharmaceutical companies structure licensing partnerships, including development responsibilities, territorial rights, and commercialization arrangements.
• Analyze Financial Terms with Confidence: Review disclosed payment structures such as upfront payments, milestone payments, and royalties, enabling accurate benchmarking of licensing deal value.
• Access Real Contract Documents: Where available, explore actual licensing agreements filed with the SEC, providing deeper insight into the contractual provisions behind real-world deals.
• Identify Active Licensing Dealmakers: Discover which companies are most active in pharmaceutical licensing and analyze their partnership strategies.
• Track Licensing Trends: Analyze licensing activity since 2020 across companies, therapeutic areas, and technologies to understand how industry partnering strategies are evolving.

What's Included in the Report

• Analysis of pharmaceutical licensing dealmaking trends since 2020
• Overview of licensing deal structures and financial models
• Review of leading licensing deals by disclosed value
• Profiles of the most active licensing dealmakers
• Detailed analysis of deals by company, therapeutic area, and technology type
• A comprehensive deal directory covering all licensing deals announced since 2020
• Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

• Rights granted or optioned under the license
• Upfront payments, milestone payments, and royalty structures
• Intellectual property ownership and licensing scope
• Development, manufacturing, and commercialization responsibilities
• Exclusivity provisions and territorial rights
• Contract duration and termination provisions

Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in licensing dealmaking
2.1. Introduction
2.2. Definition of licensing deal
2.3. Trends in licensing deals since 2020
2.3.1. Licensing dealmaking by year
2.3.2. Licensing dealmaking by phase of development
2.3.3. Licensing dealmaking by industry sector
2.3.4. Licensing dealmaking by therapy area
2.3.5. Licensing dealmaking by technology type
2.3.6. Licensing dealmaking by most active company
2.4. Reasons for entering into licensing partnering deals
2.5. The future of licensing deals
Chapter 3 - Overview of licensing deal structure
3.1. Introduction
3.2. Licensing agreement structure
Chapter 4 - Leading licensing deals
4.1. Introduction
4.2. Top licensing deals by value
Chapter 5 - Top 25 most active licensing dealmakers
5.1. Introduction
5.2. Top 25 most active licensing dealmakers
Chapter 6 - Licensing deals including contracts directory
6.1. Introduction
6.2. Licensing deals with contracts
Deal directory
Deal directory - licensing dealmaking by companies A-Z
Deal directory - licensing dealmaking by therapy area
Deal directory - licensing dealmaking by technology type

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN12032026004107003653ID1110853416